Abstract
Abstract A previous case-control study reported a positive association between mitochondrial DNA (mtDNA) copy number in peripheral blood and breast cancer risk. However, data on mtDNA copy number and breast cancer risk in prospective cohorts is lacking. We evaluated the prospective association between mtDNA copy number and breast cancer risk in the Singapore Chinese Health Study. We conducted a nested case-control study of 183 incident breast cancer cases with pre-diagnostic blood samples and 529 individually matched control women who were free of breast cancer. The mtDNA copy number was measured using real time PCR. Conditional logistic regression methods were employed to examine the association between mtDNA copy number and breast cancer risk. Overall, there was no association between mtDNA copy number and breast cancer after adjustment for potential confounders (p=0.37). Among participants who donated a blood sample within 3 years of breast cancer diagnosis women in the second and third tertile of mtDNA copy number had a significantly increased breast cancer risk as compared to those in the lowest mtDNA copy number tertile (odds ratio (95% confidence interval): 1.84 (0.93-3.64) and 2.13 (1.09-4.17) respectively; p for trend = 0.03). There was no association between mtDNA copy number and breast cancer risk among women who donated a blood sample ≥ 3 years before breast cancer diagnosis (p for trend = 0.73). This study supports a prospective association between increased mtDNA copy number and breast cancer risk that is dependent on the time interval between blood collection and breast cancer diagnosis. Citation Format: Bharat Thyagarajan, Renwei Wang, Helene Barcelo, Heather Nelson, Woon Puay Koh, Jian Min Yuan. Mitochondrial DNA copy number is prospectively associated with breast cancer risk. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1339. doi:10.1158/1538-7445.AM2013-1339
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.